Edesa Biotech, Inc.EDSANASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank57
5Y CAGR-47.3%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-47.3%/yr
Long-term compound
Percentile
P57
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 2.66% |
| 2024 | -2.64% |
| 2023 | -15.70% |
| 2022 | -12.19% |
| 2021 | 69.52% |
| 2020 | 65.38% |
| 2019 | -25.82% |
| 2018 | -6.37% |
| 2017 | -11.37% |
| 2016 | 2.95% |